FDA Approves Gilead’s HIV Drug Descovy

Gilead Sciences Inc. April 4 said that the FDA has approved Descovy (emtricitabine 200 milligram (mg)/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for treating HIV.

Descovy is indicated in combination with other antiretroviral agents for treating HIV-1 infection in adults and pediatric patients 12 years of age and older, the Foster City, Calif.-based company said. Descovy isn’t indicated for use as pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults at high risk.

TAF, part of Descovy, is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose ...